Stocks and Investing Stocks and Investing
Thu, June 27, 2024

Mohit Bansal Maintained (BMRN) at Buy with Increased Target to $115 on, Jun 27th, 2024


Published on 2024-10-28 12:07:45 - WOPRAI, Mohit Bansal
  Print publication without navigation


Mohit Bansal of Wells Fargo, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Increased Target from $110 to $115 on, Jun 27th, 2024.

Mohit has made no other calls on BMRN in the last 4 months.



There are 7 other peers that have a rating on BMRN. Out of the 7 peers that are also analyzing BMRN, 4 agree with Mohit's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Joel Beatty of "Baird" Downgraded from Buy to Hold and Decreased Target to $72 on, Friday, May 17th, 2024
  • Whitney Ijem of "Canaccord Genuity" Maintained at Hold with Decreased Target to $89 on, Friday, April 26th, 2024
  • David Lebovitz of "Citigroup" Maintained at Hold with Decreased Target to $91 on, Thursday, April 25th, 2024
  • George Farmer of "Scotiabank" Maintained at Hold with Increased Target to $85 on, Thursday, April 25th, 2024


These are the ratings of the 3 analyists that currently disagree with Mohit


  • Cory Kasimov of "Evercore ISI Group" Initiated at Buy and Held Target at $113 on, Tuesday, May 14th, 2024
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $112 on, Friday, April 26th, 2024
  • Olivia Brayer of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $110 on, Thursday, April 25th, 2024
Contributing Sources